N-[2-[[5-氟-2-[[2-甲氧基-4-(4-吗啉基)苯基]氨基]-4-嘧啶基]氨基]苯基]甲磺酰胺 | 1191911-26-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: N-[2-[[5-氟-2-[[2-甲氧基-4-(4-吗啉基)苯基]氨基]-4-嘧啶基]氨基]苯基]甲磺酰胺
• 中文别名: CZC-25146游离态
• 英文名称: N-(2-(2-(2-Methoxy-4-morpholinophenylamino)-5-fluoropyrimidin-4-ylamino)phenyl)methanesulfonamide
• 英文别名: N-[2-[[5-fluoro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]phenyl]methanesulfonamide
• CAS: 1191911-26-8
• 化学式: C₂₂H₂₅FN₆O₄S
• 分子量: 488.5
• InChiKey: XXHHOTZUJIXPJX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  126
• 氢给体数：
  3
• 氢受体数：
  11

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS<br/>[FR] COMPOSÉS DE PYRIMIDINE ORTHO-SUBSTITUÉS EN TANT QU'INHIBITEURS DE JAK
  申请人：CELLZOME LTD

  公开号：WO2011029807A1

  公开（公告）日：2011-03-17

  The present invention relates to compounds of formula (I), wherein X1 to X3, R, R2 to R7 and AA have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

  本发明涉及化合物的结构式（I），其中X1到X3，R，R2到R7和AA的含义如描述和权利要求中所述。所述化合物可用作JAK抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导的疾病。本发明还涉及包括所述化合物的药物组合物、该类化合物的制备以及用作药物的用途。
• ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAK INHIBITORS
  申请人：Harrison Richard John

  公开号：US20120172385A1

  公开（公告）日：2012-07-05

  The invention relates to compounds of formula (I) wherein X 1 to X 3 , R, R 2 to R 7 and AA have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

  本发明涉及公式(I)的化合物，其中X1至X3、R、R2至R7和AA的含义如说明书和权利要求中所述。所述化合物可用作JAK抑制剂，用于治疗或预防免疫、炎症、自身免疫、过敏性疾病和免疫介导疾病。本发明还涉及包括上述化合物的制药组合物、制备这些化合物以及用作药物的用途。
• LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME
  申请人：Dana Farber Cancer Institute, Inc.

  公开号：EP3778604A1

  公开（公告）日：2021-02-17

  Compounds having the formula I, II, or III: are provided. Compounds of the present disclosure are useful for the treatment of neurodegenerative diseases, such as Parkinson's Disease.

  具有式 I、II 或 III 的化合物： 的化合物。本公开的化合物可用于治疗神经退行性疾病，如帕金森病。
• Compositions and methods for treating Dengue virus infection
  申请人：The J. David Gladstone Institutes

  公开号：US10004751B2

  公开（公告）日：2018-06-26

  The present disclosure provides methods of treating a flavivirus infection, and compositions for use in the methods.

  本公开提供了治疗黄病毒感染的方法以及用于这些方法的组合物。
• Treatment or prevention of an intestinal disease or disorder
  申请人：The United States of America, as represented by the Secretary, Department of Health & Human Services

  公开号：US10058559B2

  公开（公告）日：2018-08-28

  Disclosed are methods of treating or preventing an intestinal disease or disorder comprising administering to a subject a modulator of leucine rich repeat kinase 2 (LRRK2) in an amount effective to treat or prevent an intestinal disease or disorder and methods of determining the susceptibility or risk of a subject to develop an intestinal disease.

  所公开的是治疗或预防肠道疾病或紊乱的方法，包括向受试者施用有效量的富亮氨酸重复激酶 2 (LRRK2) 调节剂以治疗或预防肠道疾病或紊乱，以及确定受试者患肠道疾病的易感性或风险的方法。